Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Calcium Dobesilate × Dermatologic × Clear all

Phase

Phase 2 3 Phase 1 3 Phase NA 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 42 Lymphoid 16 Other hematologic neoplasm 12 Myeloid 3 Thoracic 2 Gastrointestinal 2 Tumor-Agnostic 1 Head & Neck 1 Gynecologic 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 72 Nivolumab 52 Ipilimumab 40 Cyclophosphamide 34 aldesleukin 26 Interleukin-2 23 Temozolomide 17 fludarabine 16 fludarabine phosphate 15 Biopsy 11 trametinib 10 dabrafenib 10 Radiotherapy 10 avelumab 8 Paclitaxel 8 Dacarbazine 8 Cisplatin 8 Bevacizumab 8 sargramostim 7 cemiplimab 7 lenvatinib 6 binimetinib 6 Magnetic Resonance Spectroscopy 6 Fluorouracil 6 spartalizumab 5 poly ICLC 5 montanide ISA 51 5 epacadostat 5 Vemurafenib 5 Specimen Handling 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02862145 2016-09-27

MRX34-102

Mirna Therapeutics, Inc.

Phase 1/2 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡